3.33MMarket Cap-0.60P/E (TTM)
4.8758High4.6025Low9.53KVolume4.8500Open4.7900Pre Close45.13KTurnover1.58%Turnover RatioLossP/E (Static)724.15KShares15.696052wk High0.40P/B2.77MFloat Cap2.414052wk Low--Dividend TTM602.92KShs Float3210.0000Historical High--Div YieldTTM5.71%Amplitude2.4000Historical Low4.7360Avg Price1Lot Size
InMed Pharmaceuticals Stock Forum
InMed Enters Into Standby Equity Purchase Agreement
InMed Pharmaceuticals (NASDAQ: INM) has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, , managed by Yorkville Advisors Global LP, on December 13, 2024. The agreement allows InMed to sell up to $10 million of common shares over a 36-month period.
The shares will be priced at 97% of the Market Price during a specified three-day pricing period. The total shares issuable are to 19.99% of...
newsfile· 5 mins ago
Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effectsSupports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritusAnti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules
InMed Pharmaceuticals (NASDAQ: INM) has announced a 1-for-20 share consolidation to regain compliance with Nasdaq's listing requirements. The consolidation will reduce outstanding shares from 14,361,550 to approximately 718,078 common shares. The post-consolidation shares are expected to begin trading on Nasdaq Capital Market on November 15, 2024. The trading symbol 'INM' will remain unchanged...
No comment yet